Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / InMed Pharmaceuticals Inc.

M&Acompleted an acquisition (SEC 8-K)16 Nov 2026

InMed Pharmaceuticals Inc.

16 Nov 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
16 Nov 2026
Ticker
INM
Role
Completed an acquisition
Sector
Pharma and biotech
Sic
2834
Items
2.01, 2.02, 9.01
Summary
Risk Factors The risks associated with Mentari's business and operations are described in the Company's definitive proxy statement/prospectus and management information circular filed on Form S-4 with the U.S.
Location
Vancouver
SEC CIK
1728328
Reference
0001193125-26-462017
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at InMed Pharmaceuticals Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

Across AOS Research

Other records for InMed Pharmaceuticals Inc. in our registers.

More in Completed an acquisition

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.